This Company Is Maximizing its Growth in an Emerging Sector With a Three-Pillar Strategy

By Mark Sheridan


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.


Creso Pharma – a Unique Stock Already Attracting the Biggest Names in the Green Business.

When you first look at what Creso Pharma (ASX:CPH) has been doing in the cannabis and CBD spaces, it’s impossible not to notice the calibre of its team.

This is a young firm operating in an emerging market, but the level of experience and insight its board has to offer is among the best in the industry.

Consider Dr Miri Halperin Wernli, PhD…

She has over twenty-five years of experience in strategic and operational leadership across the pharmaceutical and biomedical industries, and she’s currently the President of MindMedicine (OTC:MMEDF), a company that itself has a market cap of US$1.2 billion.

Or take Boaz Wachtel…

He’s well-known for initiating and helping to implement the National Medical Cannabis Program in Israel. Not to mention the fact he was also a part of the body (the European Coalition for Just and Effective Drug Policies) that recently drove through the UN’s reduction of cannabis to a Schedule 1 substance.

Then, of course, there’s Jorge Wernli…

He’s a sought-after expert in developing access for both well-established pharmaceuticals and brand-new start-ups into different markets worldwide such as the EU, Latin America, and Asia. In fact, he has over thirty years of experience dealing with international governments and negotiating strong, profitable agreements bringing improved health outcomes to patients and customers.

But, perhaps most interesting – especially when it comes to recognizing why Creso Pharma is such an exciting investment opportunity right now – is the fact that Bruce Linton is on board as a Strategic Advisor.

Who’s Bruce Linton?

Well, as the founder, former Chairman of the Board, and co-Chief Executive Officer of Canopy Growth Corporation (TSX:WEED), he is without doubt one of the world’s leading cannabis industry executives.

During the six years he was at Canopy, he led it from a little-known start-up to a company with a market cap of roughly US$15 billion.

Today, he serves as Executive Chairman of GAGE Cannabis, and Director of MindMedicine (OTC:MMEDF).

And that’s not to mention that he is co-Chairman and former Chief Executive Officer of tech company Martello Technologies Group (CVE:MTLO), co-Founder of Ruckify Software, and an active investor in cannabis companies SLANG Worldwide (CSE:SLNG) and OG DNA Genetics.

So, the real question is:

What is it about Creso Pharma that is attracting these industry giants?

The Three Pillars Priming Creso For Massive Growth

You don’t need to scratch too deep below the surface to see why Creso Pharma could be on a similar path to Canopy.

It starts when you look at the three core pillars of the business.

First, there is the part of the firm based in Canada focused on the cultivation, processing, and sale of marijuana.

This fully-licenced arm – called Mernova Medicinal Inc. – is ideally positioned to supply wholesale and retail recreational and medical cannabis to Canada, the US, and Europe.

Mernova began retail sales in Canada in 2020 with purchase orders received from Nova Scotia, the Yukon, and New Brunswick.

Managed by two former Canopy executives – Jack Yu and Isaac Allen – this pillar of Creso Pharma has even been formally recognized by the Ontario Cannabis Retail Corporation.

This effectively gives it the green light to become a supplier to Canada’s largest recreational market.

As part of a strategic push to diversify its product lines, Mernova will also be launching Hash and Pre-Roll Joint products into the rapidly growing Canadian recreational market in Q1 2021. But remember, this is only one of the pillars on which Creso Pharma is built.

To consider the other two, we must travel to Switzerland…

You see, it’s in Europe where Creso Pharma is developing, manufacturing, and selling finished CBD-based products that use innovative delivery systems for two very distinct markets: humans and animals.

Together, these three different business pillars give Creso Pharma access to several markets all billed to boom worldwide.

There’s no wonder the likes of Bruce Linton are so keen to be involved.

But still, when you dig deeper, the exciting opportunity Creso Pharma presents becomes even clearer…


A More Effective Means of CBD Delivery


Creso Pharma’s recreational cannabis pillar is already generating strong revenues and is growing at pace.

With plans to broaden its product range and expand into new regions, the opportunity here is exciting enough.

Remember, forecasts put the value of the recreational cannabis industry at almost US$74 billion globally, by 2027.

The bottom line is it makes sense to be in this market.

So when you add in Creso Pharma’s two other pillars of business – CBD-based products for humans and those for animals too – things start to get really interesting.

The CBD-based products we are talking about here are more specifically known as nutraceuticals.

They are formulations derived from cannabinoids found in cannabis, but they are not psychoactive.

Instead, CBD nutraceuticals work in conjunction with the body’s natural endocannabinoid system to provide nutritional value and help relieve various symptoms such as pain, anxiety, and stress.

It’s a booming market, too. CBD sales in the US alone are expected to pull in around US$20 billion by 2024.

But, there’s a problem…

Most of the current products available on the market have what’s called a low ‘bioavailability rate’.

This means that because of the way they’re consumed – usually orally, through the digestive system – a lot of the good stuff doesn’t actually get absorbed into the bloodstream.

Creso Pharma is solving this.

Under the guidance of Dr. Gian Trepp – a PhD in molecular biology and seasoned pharma executive – the firm has developed its own proprietary and patented ways of delivering its products.

In fact, it has developed options for administering them through skin and muscle absorption (topical) and – perhaps most effectively – through absorption in the mouth (buccal) or under the tongue (sublingual).

Furthermore, it has developed a new hemp-flour based technology that allows for the extract-free manufacturing of CBD products. This provides a stronger entourage effect from plant ingredients, and ensures regulatory compliance.

With its range of cannaQIX CBD products, Creso Pharma has produced a simple lozenge people can dissolve in the mouth.

This means that up to 90% of the ingredients reach the bloodstream compared to as little as 20% from a standard, swallowed pill, due to its superior bioavailability.

And on the animal front too, Creso Pharma has developed what are known as “complementary feed” products.

These can be mixed with existing pet food, dissolved in water, or even fed to the animal from the owner’s hand.

CBD products for pets may sound like an unusual opportunity.

But consider that this sector alone is forecast to make up 3-5% of all CBD sales in the US by 2025.

It’s a big market that is only just beginning to be understood.

Bottom line is, Creso Pharma has found a way to produce quality products with the rigour and discipline of a pharma company, and deliver them in a commercially effective way.

It’s another reason why the firm looks set to be a dominant force in this space, and why it makes sense to get in on the action now.

Indeed, Creso Pharma’s potential for growth has no borders…

Sights Set on a Global Revolution

Already well established in Canada and Europe – thanks in part to its already-booming recreational and CBD arms – Creso Pharma has set its sights much further afield.

Of course, there is a huge opportunity in the US, with regulation around cannabis use already easing, and the Democratic Party now in power.

The cannabis market in the US alone is forecast to be worth a staggering US$35 billion as soon as 2025.

Creso Pharma Ltd is perfectly positioned to ride that wave up.

But the fact is, the company has already launched into markets elsewhere too. It has products available all over Europe, the African continent, Latin America, New Zealand and Australia…

It has even signed a letter of intent with a laboratory in Pakistan, to move into that market as well.

The reach here is truly global.

So, it’s clear why people like Bruce Linton are so keen to be a part of Creso Pharma Ltd.

This is a company with big plans.

If you missed out on Canopy’s momentous rise last time around, then this could be your second chance to make massive returns.




This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by CRESO PHARMA LTD. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of five hundred thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.


In this article:


Author: Mark Sheridan

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter